In the study by Cao et al [34], a 605-gene NGS panel was used to analyze tumor and plasma samples of CRC patients, and from 35 patients with KRAS status available in both tumor and plasma, the calculated sensitivity was 75.0% and specificity was 82.6%. The gene discussed is KRAS; the disease is colorectal carcinoma.